Biotechnology News and Research

RSS

CORD I phase III clinical trial results of XIAFLEX published

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that The New England Journal of Medicine (NEJM) has published in its September 3rd edition, the Company's pivotal CORD I Phase III clinical trial of XIAFLEX (collagenase clostridium histolyticum) a novel, first-in-class, biologic for the nonsurgical treatment of Dupuytren's contracture.

3 Sep 2009

Clinical research paper on 2D gel electrophoresis for identifying protein biomarkers

Transgenomic, Inc. and Power3 Medical Products, Inc. (OTC Bulletin Board: PWRM) today announced the advance on-line publication of a clinical research paper entitled "Abnormal Serum Concentrations of Proteins in Parkinson's Disease" in the scientific journal Biochemical and Biophysical Research Communications.

3 Sep 2009

MIPI to sub-license the Onalta brand 90-Y edotreotide radiotherapeutic

Molecular Insight Pharmaceuticals, Inc. today announced that it has completed an agreement to sub-license its Onalta™ brand 90-Y edotreotide radiotherapeutic in certain countries in Europe, the Middle East, North Africa, Russia and Turkey to BioMedica Life Sciences, S.A., Athens, Greece.

3 Sep 2009

Kane Biotech announces Harvard Medical School's research publication on its DispersinB product

Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms is pleased to announce a recent research publication by Harvard Medical School on their finding of DispersinB® enzyme specific substrate in Acinetobacter baumannii (A. baumannii).

3 Sep 2009

Clinical trial results of sumatriptan published in a journal

NovaDel Pharma Inc. announced that an article titled “Rapid Oral Transmucosal Absorption of Sumatriptan, and Pharmacodynamics in Acute Migraine” was published online on June 22, 2009 in the peer-reviewed journal Headache: The Journal of Head and Face Pain.

3 Sep 2009

Novel oncology therapeutic evaluation in Biomerk Tumorgraft platform

Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.

3 Sep 2009

BioMS Medical update on dirucotide development

BioMS Medical Corp. (TSX: MS), today provided an update on developments in respect of dirucotide, its drug candidate for multiple sclerosis (MS).

2 Sep 2009

NCI to announce the results of follow-up study of PharmaGap's lead drug GAP-107B8

PharmaGap Inc. (TSX-V: GAP; OTC.BB: PHRGF) ("PharmaGap" or "the Company") today announced that results are expected during September from the United States National Cancer Institute (NCI) follow-up study of the company's lead drug GAP-107B8.

2 Sep 2009

Danaher to acquire mass spectrometry business from Life Technologies Corporation

Life Technologies Corporation (NASDAQ:LIFE) today announced it has signed a definitive agreement to sell its ownership stake in its mass spectrometry business, operated as a joint venture, to Danaher Corporation (NYSE:DHR) for $450 million in cash. Danaher has also signed an agreement to acquire Life Technologies’ joint venture partner in the mass spectrometry business, MDS Analytical Technologies, a division of MDS Inc. (NYSE:MDZ). The transaction is expected to close in the fourth quarter of 2009.

From Danaher 2 Sep 2009

Selexis SA and NKT Therapeutics sign research services agreement

Selexis SA ("Selexis") and NKT Therapeutics, Inc. ("NKTT") announce today that they have entered into a research services agreement whereby Selexis will screen antibody variants and generate high performance CHO-based production cell lines using their novel platform named INTEGRA-D2M(TM).

2 Sep 2009

Lupus Foundation of America to educate people with lupus on clinical trial participation

It has been more than 50 years since the U.S. Food and Drug Administration (FDA) last approved a new medicine specifically for lupus – when Dwight D. Eisenhower was president. Existing treatments have been "borrowed" from other disorders and the risk/benefit ratio of these treatments is far from optimal. However, hope is on the horizon.

2 Sep 2009

Public-private collaboration to fund research on health, diet and green technology

A total of £7M funding has been announced today by two public-private collaborations led by the Biotechnology and Biological Sciences Research Council (BBSRC).

2 Sep 2009

FDA: Randomized clinical trial necessary to better interpret Clolar’s efficacy and safety in adult AML

Genzyme Corporation (Nasdaq: GENZ) announced today that the FDA’s Oncologic Drugs Advisory Committee voted 9 to 3 that a randomized, controlled trial is needed to support the currently proposed label expansion for Clolar® (clofarabine) in adult myeloid leukemia (AML). The committee found that the single-arm clinical study results submitted to support the label expansion showed Clolar was an active agent in acute AML patients, but concluded that a randomized clinical trial should be necessary to better interpret Clolar’s efficacy and safety in the proposed patient population.

2 Sep 2009

Monsanto sings a non-exclusive research and commercial license agreement with Cellectis

Monsanto Company (NYSE:MON) today announced a non-exclusive research and commercial license agreement with France-based Cellectis S.A. (Paris:ALCLS), a biotechnology company specialized in genome engineering, for broad use of its meganuclease technology in plants.

2 Sep 2009

Stock split anounced by United Therapeutics Corporation

United Therapeutics Corporation (Nasdaq: UTHR) announced today that its Board of Directors has approved and declared a stock split. The stock split will be effected in the form of a stock dividend, in which one share of United Therapeutics common stock will be distributed for each share of common stock issued and outstanding (or held in treasury) at the close of business on the record date, September 14, 2009.

2 Sep 2009

Vitro Diagnostics develops technology and products for cell-based cancer therapy

Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, announced advances in its adult stem cell products and technology with application to cell-based therapy of cancer. With the passing of Senator Edward Kennedy from brain cancer, we are reminded of such aggressive cancers without effective treatment.

2 Sep 2009

JAMA study reveals the genetic signature of brain cancer

A pair of studies in the July 15 issue of the Journal of the American Medical Association (JAMA) spell out how much closer science has come to unraveling the genetic signature of brain cancer, according to a researcher at the University of Alabama at Birmingham (UAB). Boris Pasche, M.D., Ph.D., director of the UAB Division of Hematology and Oncology, believes these studies represent a new vanguard in the still-changing field of DNA analysis.

2 Sep 2009

Liberal hospice insurance benefits improve health care for patients with advanced illnesses

Patients with advanced illnesses more than doubled their use of hospice care when a major national health plan made hospice care more readily accessible, according to the results of a comparative study published in Journal of Palliative Medicine, a peer-reviewed publication from Mary Ann Liebert, Inc.(www.liebertpub.com).

2 Sep 2009

Altered gene network interaction plays an important role in brain tumors

The interaction between a network of altered genes appears to play an important role in the development and progression of brain tumors, according to a study in the July 15 issue of JAMA.

1 Sep 2009

Oncolytics Biotech obtains 32nd U.S. Patent grant

Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted its 32nd U.S. Patent, # 7,582,289, entitled "Viruses for the Treatment of Cellular Proliferative Disorders." The patent claims cover methods of using modified parapoxvirus orf virus to treat Ras-mediated cancers.

1 Sep 2009

Biotechnology News and Research

CORD I phase III clinical trial results of XIAFLEX published

Clinical research paper on 2D gel electrophoresis for identifying protein biomarkers

MIPI to sub-license the Onalta brand 90-Y edotreotide radiotherapeutic

Kane Biotech announces Harvard Medical School's research publication on its DispersinB product

Clinical trial results of sumatriptan published in a journal

Novel oncology therapeutic evaluation in Biomerk Tumorgraft platform

BioMS Medical update on dirucotide development

NCI to announce the results of follow-up study of PharmaGap's lead drug GAP-107B8

Danaher to acquire mass spectrometry business from Life Technologies Corporation

Selexis SA and NKT Therapeutics sign research services agreement

Lupus Foundation of America to educate people with lupus on clinical trial participation

Public-private collaboration to fund research on health, diet and green technology

FDA: Randomized clinical trial necessary to better interpret Clolar’s efficacy and safety in adult AML

Monsanto sings a non-exclusive research and commercial license agreement with Cellectis

Stock split anounced by United Therapeutics Corporation

Vitro Diagnostics develops technology and products for cell-based cancer therapy

JAMA study reveals the genetic signature of brain cancer

Liberal hospice insurance benefits improve health care for patients with advanced illnesses

Altered gene network interaction plays an important role in brain tumors

Oncolytics Biotech obtains 32nd U.S. Patent grant

Biotechnology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News